The GST 2.0 reforms, effective from 22 September 2025, mark the most significant tax update in the Indian pharmaceutical sector since 2017. Announced during the 56th GST Council meeting, these Next-Gen reforms introduce a simplified three-tier tax structure—5%, 18%, and 40%—with a focus on making healthcare more affordable.
Under the 2026 GST regime, nearly all categories of medicines have been moved to the 5% “Merit” slab, while essential life-saving treatments are fully exempt from GST.
New GST Rates on Medicine (2026)
Medicine / Healthcare Category |
Old GST Rate (Before 22 Sep 2025) |
New GST Rate (Effective 22 Sep 2025) |
33 Specified Life-saving Drugs (e.g., cancer, rare diseases) |
12% |
Nil (0%) |
Specific Cancer Drugs (e.g., Trastuzumab, Osimertinib) |
5% |
Nil (0%) |
Allopathic Medicines (general formulations) |
12% |
5% |
Ayurvedic, Unani, Siddha & Homeopathic Medicines |
12% |
5% |
Diagnostic Kits & Reagents (e.g., COVID, malaria, hepatitis) |
12% |
5% |
Medical Devices (glucometers, thermometers, spectacles) |
12% / 18% |
5% |
Bandages, gauze & surgical dressings |
12% |
5% |
Medical-grade oxygen |
12% |
5% |
Individual health & life insurance premiums |
18% |
Nil (0%) |
Sanitary napkins & tampons |
Nil / 12%* |
Nil (0%) |
Note: While most sanitary products were already exempt, the 2025 reform confirmed a ‘Nil’ GST rate for all clinical hygiene and baby care essentials.